CANCER IMMUNOTHERAPY: The dark side of PD-1 receptor inhibition

    loading  Checking for direct PDF access through Ovid

Abstract

Inhibiting the protein PD-1 can activate T cells that trigger immune responses against tumour cells. But it emerges that, in mice, this immunotherapy exacerbates a cancer that involves the T cells themselves. See Letter p.121

Related Topics

    loading  Loading Related Articles